Press Release: Global Liquid Biopsy Market Poised for Robust Growth Amidst Technological Advancements and Rising Demand for Non-Invasive Diagnostics
The global liquid biopsy market is experiencing significant growth, driven by technological advancements and an increasing demand for non-invasive diagnostic methods. Valued at approximately USD 4.29 billion in 2024, the market is projected to reach around USD 15.46 billion by 2033, expanding at a compound annual growth rate (CAGR) of 15.3% during the forecast period .
Market Overview
Liquid biopsy is a minimally invasive diagnostic technique that analyzes circulating biomarkers—such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes—in biological fluids like blood. This approach offers real-time insights into tumor dynamics, enabling early cancer detection, monitoring of disease progression, and assessment of treatment response. Beyond oncology, liquid biopsies are being explored for applications in prenatal testing, organ transplant monitoring, and the detection of other genetic or chronic conditions.
Key Market Drivers
- Rising Cancer Incidence and Demand for Early Detection
The increasing global prevalence of cancer necessitates efficient and accurate diagnostic tools. Liquid biopsies provide a non-invasive alternative to traditional tissue biopsies, facilitating early detection and personalized treatment strategies. In the United States alone, approximately 2 million new cancer cases and over 600,000 cancer-related deaths were anticipated in 2024 .
- Technological Advancements in Biomarker Discovery
Innovations in molecular diagnostics, particularly next-generation sequencing (NGS) and digital PCR, have enhanced the sensitivity and specificity of liquid biopsies. These advancements enable the detection of actionable genetic mutations and real-time monitoring of treatment efficacy, thereby integrating liquid biopsies into clinical workflows globally .
- Shift Towards Non-Invasive Diagnostic Techniques
Patient preference for less invasive procedures is propelling the adoption of liquid biopsies. These tests reduce the risks associated with surgical biopsies, allow for repeated sampling, and are particularly beneficial for patients with advanced-stage cancers where traditional biopsies may not be feasible.
Regional Market Insights
United States
The U.S. leads the global liquid biopsy market, attributed to its high cancer incidence rates, advanced healthcare infrastructure, and substantial investments in research and development. The market is expected to grow from USD 1.21 billion in 2024 to approximately USD 4.25 billion by 2033, at a CAGR of 14.99% .
Germany
Germany is at the forefront of the European liquid biopsy market, driven by its robust healthcare system and emphasis on medical research. The country’s proactive adoption of innovative diagnostic technologies and collaborations between medical research institutions and pharmaceutical companies are fostering market growth.
China
China’s liquid biopsy market is expanding rapidly, fueled by a high cancer burden and improvements in healthcare infrastructure. Government initiatives aimed at increasing access to advanced diagnostic tools and significant investments in biotechnology are positioning China as a key player in the global market.
Brazil
In Latin America, Brazil is emerging as a leader in liquid biopsy adoption. The country’s efforts to modernize its healthcare system and improve cancer diagnostics, coupled with government initiatives and investments in biotechnology, are enhancing the growth of liquid biopsy technologies.
Recent Developments
- F. Hoffmann-La Roche Ltd.: In October 2020, received FDA approval for a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) therapies. In June 2022, partnered with the Lung Cancer Research Foundation and Lung Cancer Mutation Consortium to evaluate actionable drivers in early-stage lung cancer .
- Thermo Fisher Scientific Inc.: In August 2023, released the first assays to measure myeloid measurable residual disease (MRD) using both DNA and RNA. In November 2022, introduced digital PCR liquid-biopsy assays for its Applied Biosystems absolute Q dPCR system .
- Guardant Health: In January 2023, received FDA approval for Guardant360 CDx, a liquid biopsy assay for ESR1 mutant breast cancer diagnosis. In December 2022, partnered with Susan G. Komen to conduct clinical studies using Guardant Reveal, a blood-based test for breast cancer detection .
- Illumina, Inc.: In November 2023, launched TruSight Oncology 500 ctDNA v2, a new generation liquid biopsy assay for genomic profiling. In 2021, collaborated with Bristol Myers Squibb to develop companion diagnostics for therapy selection .
- QIAGEN N.V.: In May 2023, introduced the Therascreen EGFR Plus RGQ PCR Kit for detecting sensitive mutations in the EGFR gene. In April 2023, launched QIAseq targeted cfDNA ultra panels to facilitate research on cancer and other diseases .
Market Segmentation
By Product Type
- Kits & Reagents
- Platforms & Instruments
- Services
By Application
- Cancer Therapeutic Applications
- Reproductive Health
- Other Therapeutic Areas
By Circulating Biomarker
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
By End-User
- Hospitals
- Diagnostic Laboratories
- Point-of-Care Testing
- Academic Institutes
- Others
By Region
- Americas: United States, Canada, Mexico, Brazil
- Europe: United Kingdom, Germany, France, Italy, Spain, Netherlands
- Asia-Pacific: China, Japan, India, South Korea, Australia
- Middle East & Africa: United Arab Emirates, South Africa, Rest of the World
Company Profiles
The report provides comprehensive analyses of key players in the liquid biopsy market, including:
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories
- Thermo Fisher Scientific Inc.
- Johnson & Johnson
- Biocept Inc.
- Guardant Health
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- QIAGEN N.V.
- Exact Sciences Corporation
Each company profile encompasses an overview, recent developments, and revenue analysis.
Conclusion
The global liquid biopsy market is on a trajectory of robust growth, underpinned by technological innovations and a paradigm shift towards non-invasive diagnostics. As the demand for personalized medicine intensifies, liquid biopsies are poised to become integral to disease detection and management strategies worldwide.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:[email protected]
